RUNX1 and leukemia: Yamamoto et al., [134] reported that miR-133 in leukemic cells targets the Ecotropic viral integration site 1 (Evi1) which upregulated the drug sensitivity and suggested that miR-133 can be a potential therapeutic target for Evi1-overexpressing leukemia.